GlassScriptPhysician profile
Robert L Wren
NPI 1508295460
$7,416.55
in general payments reported to CMS, 2019-2025
30 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,893 · 2022: $697 · 2023: $1,092 · 2024: $1,921 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,826.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Glaxosmithkline, LLC. | $1,058.60 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $900.22 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $866.98 | 2021-2025 | |
| Lilly USA, LLC | $756.90 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $629.92 | 2022-2025 | |
| Novo Nordisk INC | $567.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Linus Health, INC. | $209.98 | 2023 | |
| Amgen INC. | $165.26 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $145.81 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $107.01 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $101.96 | 2021-2022 | |
| Inspire Medical Systems, INC. | $99.95 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $98.03 | 2022 | |
| Astellas Pharma US INC | $92.98 | 2024-2025 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.75 | 2021 | |
| Merck Sharp & Dohme LLC | $54.47 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.88 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $35.71 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.44 | 2024 | Xifaxan, Trulance |
| Seqirus USA INC | $28.27 | 2025 | Flucelvax, Fluad |
| Optinose US, INC. | $23.70 | 2021 | |
| Mylan Specialty L.P. | $21.37 | 2022 | |
| Azurity Pharmaceuticals, INC. | $20.53 | 2025 | Azmiro |
| Corcept Therapeutics | $17.69 | 2025 | Korlym |
| Antares Pharma, INC. | $16.46 | 2022 | |
| Edwards Lifesciences Corporation | $15.90 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Paratek Pharmaceuticals, INC. | $15.10 | 2024 | Nuzyra |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.80 | 2024 | Rexulti |
| Shield Therapeutics INC | $13.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.